Tech Company Inital Public Offerings
Nurix Therapeutics IPO
On 7/23/2020, Nurix Therapeutics went public.
Transaction Overview
Company Name
Announced On
7/23/2020
Transaction Type
IPO
Amount
$209,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: to fund the development of NX-2127, to fund the development of NX-1607, to fund the development of other preclinical programs; and any remaining amounts to conduct research, fund the further development of our technology platform, broaden our pipeline of product candidates and for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1700 Owens St. 205
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Website
Email Address
Overview
Nurix Therapeutics (Nasdaq: NRIX) is focused on the discovery and development of small molecule inhibitors of ubiquitin ligases to treat a broad range of proliferative and degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Sands
Vice President
Jean Chang
Vice President
Cristiana Guiducci
VP - Bus. Development
Pierre Beaurang
VP - Finance
Hans Houte
VP - General Counsel
Christine Ring
VP - R & D
Gwenn Hansen
Browse more venture capital transactions:
Prev: 7/23/2020: Meemo venture capital transaction
Next: 7/23/2020: Misfits Market venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs